Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (“ADSs”) at the initial public offering price of $17.25 per ADS less underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Ascentage Pharma in the Offering will increase to 8,260,144 ADSs and the aggregate gross proceeds to Ascentage Pharma will be approximately $142.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Ascentage Pharma. The closing of the over-allotment option is subject to customary closing conditions.

J.P. Morgan and Citigroup acted as joint book-running managers for the offering.

About Ascentage Pharma

Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol “AAPG” since January 2025.

Contacts

Investor Relations

Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777

Stephanie Carrington
ICR Healthcare
Stephanie.Carrington@icrhealthcare.com
(646) 277-1282 

Media Relations

Sean Leous
ICR Healthcare
Sean.Leous@icrhealthcare.com
(646) 866-4012

Staff

Recent Posts

Custom Health Enters into Definitive Agreement to Complete Business Combination with Queue Ventures

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Custom Health, Inc. ("Custom Health"), a…

2 hours ago

Vaniam Group™ Introduces Vaniam Intelligence™: Purpose-Built AI, Guided by Human Insight

CHICAGO, Ill., May 30, 2025 /PRNewswire/ -- Vaniam Group™, a leader in medical communications, is…

2 hours ago

Provider Network Holdings Appoints Dr. Edith A. Perez, M.D. as Chief Medical Officer of Cornerstone Specialty Network

PEARLAND, Texas, May 30, 2025 /PRNewswire/ -- Cornerstone Specialty Network ("Cornerstone"), a leading provider of…

2 hours ago

California Students Recognized for Designing Digital Interventions in Support of Teen Mental Health and Wellness

Youth-led solutions support healthier tech use and peer wellness SACRAMENTO, Calif., May 30, 2025 /PRNewswire/…

2 hours ago

Supply Chain Leadership Acknowledged for Paving the Way for MedTech Innovation and Growth

Sanjay Gupta from Imbed Biosciences Inc. Featured in The Wall Street Journal as a Distinguished…

2 hours ago

RingConn Smart Ring With Sleep Apnea Monitoring Launches at Target.com

LOS ANGELES, May 30, 2025 /PRNewswire/ -- Leading smart ring brand RingConn has officially expanded…

2 hours ago